(Q34675957)

3 August 2017

title

From a multipotent stilbene to soluble epoxide hydrolase inhibitors with antiproliferative properties (English)

1 reference

Soluble epoxide hydrolase

3 August 2017

main subject

0 references

11

Helge B Bode

1 reference

3 August 2017

Franca-Maria Klingler

4

object named as

Franca-Maria Klingler

1 reference

3 August 2017

12

Ewgenij Proschak

1 reference

3 August 2017

10

Dieter Steinhilber

1 reference

3 August 2017

Estella Buscató

1

1 reference

3 August 2017

Dominik Büttner

2

1 reference

3 August 2017

Astrid Brüggerhoff

3

1 reference

3 August 2017

Julia Weber

5

1 reference

3 August 2017

Bastian Scholz

6

1 reference

3 August 2017

Aleksandra Zivković

7

1 reference

3 August 2017

Rolf Marschalek

8

1 reference

3 August 2017

Holger Stark

9

1 reference

3 August 2017

publication date

17 April 2013

1 reference

3 August 2017

1 reference

3 August 2017

volume

8

1 reference

3 August 2017

issue

6

1 reference

3 August 2017

page(s)

919-923

1 reference

Opposite regulation of cholesterol levels by the phosphatase and hydrolase domains of soluble epoxide hydrolase

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300057

Inhibition of the soluble epoxide hydrolase promotes albuminuria in mice with progressive renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300057

Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300057

Soluble epoxide hydrolase: a novel therapeutic target in stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300057

Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300057

Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300057

Epoxyeicosatrienoic acids: a double-edged sword in cardiovascular diseases and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300057

Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300057

Epoxyeicosatrienoic acids attenuate reactive oxygen species level, mitochondrial dysfunction, caspase activation, and apoptosis in carcinoma cells treated with arsenic trioxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300057

The epoxyeicosatrienoic acid-stimulated phosphorylation of EGF-R involves the activation of metalloproteinases and the release of HB-EGF in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300057

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300057

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300057

Kinase inhibition with BAY 43-9006 in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300057

Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300057

Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300057

Targeting the cancer kinome through polypharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300057

Chemical genetic discovery of targets and anti-targets for cancer polypharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300057

Network pharmacology: the next paradigm in drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300057

A quantitative analysis of kinase inhibitor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300057

The topology of drug-target interaction networks: implicit dependence on drug properties and target families

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300057

Antimitotic agents of natural origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300057

A natural product inspired tetrahydropyran collection yields mitosis modulators that synergistically target CSE1L and tubulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300057

Entomopathogenic bacteria as a source of secondary metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300057

Nematode-bacterium symbioses--cooperation and conflict revealed in the "omics" age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300057

Photorhabdus and a host of hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300057

Small molecule perimeter defense in entomopathogenic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300057

Expression and characterization of the recombinant juvenile hormone epoxide hydrolase (JHEH) from Manduca sexta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300057

Bacterial biosynthesis of a multipotent stilbene

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300057

Cancer chemopreventive activity of resveratrol, a natural product derived from grapes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300057

Dual-target virtual screening by pharmacophore elucidation and molecular shape filtering

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300057

The therapeutic journey of benzimidazoles: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300057

Development of fluorescent substrates for microsomal epoxide hydrolase and application to inhibition studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300057

Aromatic rings in chemical and biological recognition: energetics and structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300057

Biology-oriented synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300057

Complementary Screening Techniques Yielded Fragments that Inhibit the Phosphatase Activity of Soluble Epoxide Hydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300057

Natural products in cancer chemotherapy: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300057

inferred from DOI database lookup

7 January 2021

based on heuristic

Inhibition of monoamine oxidase B by selected benzimidazole and caffeine analogues

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300057

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CMDC.201300057

1 reference

3 August 2017

1 reference